Wall Street estimates the weight-loss drug market to be worth $150 billion by 2030, with Lilly and Novo together controlling ...

The drugmaker has joined an exclusive club primarily populated by technology giants, marking a significant achievement for the healthcare sector. Eli Lilly’s stock has surged more than 35% this year, ...

Eli Lilly hit a $1 trillion valuation, driven by demand for Zepbound and Mounjaro. The first health-care firm ever to join ...

The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and ...

Eli Lilly’s stock reached an all-time high of 1057.42 USD, marking a significant milestone for the pharmaceutical giant with a market capitalization now exceeding $940 billion. Over the past year, the ...

The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross ...

US stocks turned higher Friday after a week of turbulence amid rising optimism for a December interest-rate cut, while bitcoin kept tumbling as AI worries continued to weigh on investors. While stocks ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...